Vivos Therapeutics to Detail 2025 Results Amid Cash Burn Concerns
Event summary
- Vivos Therapeutics will release its full-year 2025 financial results after market close on April 15, 2026.
- A conference call is scheduled for 5:00 pm ET on April 15, 2026, to discuss the results and operational updates.
- Management will address strategic collaborations and their impact on near-term revenue growth and cash burn.
- Vivos’ CARE devices are FDA-cleared for OSA treatment in both adults and children (ages 6-17).
The big picture
Vivos Therapeutics operates in a large, underserved market for sleep apnea treatment, but faces challenges in achieving profitability. The company's reliance on strategic collaborations and acquisitions to drive growth introduces execution risk, and the forward-looking statements regarding cash flow positivity require close monitoring. The company's unique CARE device technology represents a potential differentiator, but its success hinges on broader adoption and favorable regulatory conditions.
What we're watching
- Financial Health
- The disclosed cash burn rate will be a key indicator of Vivos’ ability to sustain operations given the company's stated goal of achieving cash flow positivity, and will reveal the effectiveness of recent strategic collaborations.
- Collaboration Impact
- The actual revenue impact of strategic collaborations will need to be substantial to offset ongoing cash burn and demonstrate a viable path to profitability.
- Regulatory Risk
- Increased regulatory scrutiny within the sleep apnea treatment sector could impact Vivos’ ability to expand its market share and maintain its current FDA clearances.
Related topics